穴位注射下髎穴治疗肛提肌综合征疗效观察

Observation on the Efficacy of Point Injection at Xialiao Point(BL 34) for Levator Ani Syndrome

目的观察穴位注射下髎穴治疗肛提肌综合征的临床疗效。方法将100例肛提肌综合征患者随机分为治疗组和对照组,每组50例。治疗组采用穴位注射下髎穴治疗,对照组采用生物反馈疗法治疗。观察两组治疗前后视觉模拟评分法(VAS)评分、健康调查简表(SF-36)各项评分、肛管静息压及肛管收缩压变化情况,并比较两组临床疗效及治疗费用。结果两组治疗后VAS评分、SF-36各项评分、肛管静息压及肛管收缩压与同组治疗前比较,差异均具有统计学意义(P<0.05)。治疗组治疗后VAS评分、SF-36部分评分[生理机能(PF)、躯体疼痛(BP)、精力(VT)和社会功能(SF)评分]、肛管静息压及肛管收缩压与对照组比较,差异均具有统计学意义(P<0.05)。治疗组总有效率为88.0%,对照组为80.0%。两组临床疗效比较,差异具有统计学意义(P<0.05)。治疗组治疗费用为(327.31±13.42)元,对照组为(408.45±21.56)元,两组比较差异具有统计学意义(P<0.01)。结论穴位注射下髎穴是一种治疗肛提肌综合征的有效方法。

Objective To observe the clinical efficacy of point injection at Xialiao point（BL 34） for levator ani syndrome. Methods A hundred levator ani syndrome patients were randomly allocated to a treatment group and a control group, 50 cases each. The treatment group received point injection at Xialiao point（BL 34） and the control group was intervened by biofeedback therapy. The Visual Analogue Scale（VAS）, component scores of the MOS 36-item Short-From Health Survey（SF-36）, anal resting and squeeze pressures were recorded in the two groups before and after the treatment. The therapeutic effects and therapy costs were compared between the two groups. Results The VAS, component scores of SF-36, anal resting and squeeze pressures were significantly changed after intervention in the two groups（P〈0.05）. After treatment, the VAS, a part of the SF-36 score [physiological function（PF）, body pain（BP）, vitality（VT） and social function（SF） scores], anal resting and squeeze pressures in the treatment group were significantly different from that in the control group（P〈0.05）. The total efficacy rate was 88.0% in the treatment group versus 80.0% in the control group, and the difference was statistically significant（P〈0.05）. The therapy costs in the treatment group were（327.31±13.42） RMB and（408.45±21.56） RMB in the control group, and the difference was statistically significant（P〈0.01）. Conclusions Point injection at Xialiao point（BL 34） is an effective method for levator ani syndrome.